Biohaven Pharmaceutical Holding Company Ltd.
BHVN
BHVN was delisted on the 3rd of October, 2022.
215 hedge funds and large institutions have $3.9B invested in Biohaven Pharmaceutical Holding Company Ltd. in 2020 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 85 increasing their positions, 78 reducing their positions, and 33 closing their positions.
109% more call options, than puts
Call options by funds: $95M | Put options by funds: $45.4M
9% more repeat investments, than reductions
Existing positions increased: 85 | Existing positions reduced: 78
1% less ownership
Funds ownership: 101.63% → 100.63% (-1%)
5% less funds holding
Funds holding: 226 → 215 (-11)
10% less capital invested
Capital invested by funds: $4.34B → $3.9B (-$442M)
19% less funds holding in top 10
Funds holding in top 10: 16 → 13 (-3)
33% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 33
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$72.8M |
| 2 |
AC
Armistice Capital
New York
|
+$26.2M |
| 3 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
+$21.8M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$16.9M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$16.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$29.8M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$26.6M |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
-$25M |
| 4 |
CII
Capital International Inc
Los Angeles,
California
|
-$21.9M |
| 5 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
-$19.5M |
BHVN Hedge Fund Activity: Q3 2020 in Review
215 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Biohaven Pharmaceutical Holding Company Ltd. (BHVN) for Q3 2020, worth a combined $3.9B — down 10% from $4.34B a quarter earlier.
Sellers outnumbered buyers: 33 funds closed out of BHVN and 22 opened new positions — a net loss of 11 holders — while 78 trimmed existing stakes and 85 added.
The largest buyer was Capital World Investors, adding an estimated $72.8M. The largest seller was Vanguard Group, cutting an estimated $29.8M.
- 215 institutional investors held Biohaven Pharmaceutical Holding Company Ltd. (BHVN) as of Q3 2020, down from 226 in Q2 2020.
- Funds reported $3.9B of Biohaven Pharmaceutical Holding Company Ltd. stock for Q3 2020, down 10% quarter-over-quarter.
- 22 funds opened new Biohaven Pharmaceutical Holding Company Ltd. positions in Q3 2020 and 33 closed out, a net change of -11 holders.
- The largest Biohaven Pharmaceutical Holding Company Ltd. buyer in Q3 2020 was Capital World Investors, an estimated $72.8M added.
- The largest Biohaven Pharmaceutical Holding Company Ltd. seller in Q3 2020 was Vanguard Group, an estimated $29.8M sold.
Based on aggregated 13F filings for Q3 2020.